The DOI matches its Crossref record.
Sequence Analysis of ARI-1, a Novel OXA β-Lactamase, Responsible for Imipenem Resistance in Acinetobacter baumannii 6B92
Open accessAbstract
The sequence of the bla ARI-1 gene from imipenem-resistant Acinetobacter baumannii 6B92 has been determined. The structural gene encodes a 273-amino-acid protein which is most related to the OXA class D β-lactamases. The conserved S-T-F-K and K-T-G motifs were identified in the ARI-1 protein sequence, also named OXA-23, but significantly, a point mutation (Y→F) was identified in the Y-G-N conserved motif, also known to function in the active site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Poirel, L., & Nordmann, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01456.x · Cited by 1,051
Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae
Poirel, L., Héritier, C., Tolün, V., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.15-22.2004 · Cited by 997
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005) · Chemical Reviews · doi:10.1021/cr030102i · Cited by 913
Evans, B. A., & Amyes, S. G. B. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-13 · Cited by 815
Self-citationMechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabo, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 741
Emerging carbapenemases in Gram-negative aerobes
Nordmann, P., & Poirel, L. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00401.x · Cited by 684
Diversity, Epidemiology, and Genetics of Class D β-Lactamases
Poirel, L., Naas, T., & Nordmann, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-08 · Cited by 632
Walther-Rasmussen, J., & Høiby, N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki482 · Cited by 495
Hujer, K. M., Hujer, A. M., Hulten, E. A., Bajaksouzian, S., Adams, J. M., Donskey, C. J., Ecker, D. J., Massire, C., Eshoo, M. W., Sampath, R., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00778-06 · Cited by 480
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
The rapid spread of carbapenem-resistant Enterobacteriaceae
Potter, R. F., D’Souza, A. W., & Dantas, G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.09.002 · Cited by 403
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398
Kempf, M., & Rolain, J.-M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.10.004 · Cited by 389
Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals
Ibrahim, S., Al-Saryi, N., Al-Kadmy, I. M. S., & Aziz, S. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06690-6 · Cited by 388
Antimicrobial resistance of Acinetobacter spp. in Europe
Van Looveren, M., & Goossens, H. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00942.x · Cited by 327
Carbapenemases: a problem in waiting?
Livermore, D. M., & Woodford, N. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00128-4 · Cited by 323
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Carbapenemases: Molecular Diversity and Clinical Consequences
Poirel, L., Pitout, J. D., & Nordmann, P. (2007) · Future Microbiology · doi:10.2217/17460913.2.5.501 · Cited by 309
Sawa, T., Kooguchi, K., & Moriyama, K. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-0429-6 · Cited by 296
Hammoudi Halat, D., & Ayoub Moubareck, C. (2020) · Antibiotics · doi:10.3390/antibiotics9040186 · Cited by 287
Characterization of the Naturally Occurring Oxacillinase of Acinetobacter baumannii
Héritier, C., Poirel, L., Fournier, P.-E., Claverie, J.-M., Raoult, D., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4174-4179.2005 · Cited by 286
Afzal-Shah, M., Woodford, N., & Livermore, D. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.583-588.2001 · Cited by 282
Héritier, C., Poirel, L., Lambert, T., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3198-3202.2005 · Cited by 272
Da Silva Ferreira, M. E., Colombo, A. L., Paulsen, I., Ren, Q., Wortman, J., Huang, J., Goldman, M. H. S., & Goldman, G. H. (2005) · Medical Mycology · doi:10.1080/13693780400029114 · Cited by 158
Vandeputte, P., Tronchin, G., Larcher, G., Ernoult, E., Bergès, T., Chabasse, D., & Bouchara, J.-P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00423-08 · Cited by 117
Metadata
- Authors
- Donald, H. M., Scaife, W., Amyes, S. G. B., & Young, H.-K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-01
- Volume
- 44
- Issue
- 1
- Pages
- 196-199
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W3023926866
- Cited by
- 235
- References
- 0
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.